-
Product Insights
NewNet Present Value Model: Reneo Pharmaceuticals Inc’s REN-001
Empower your strategies with our Net Present Value Model: Reneo Pharmaceuticals Inc's REN-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Reneo Pharmaceuticals Inc’s Mavodelpar
Empower your strategies with our Net Present Value Model: Reneo Pharmaceuticals Inc's Mavodelpar report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IBI-345 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBI-345 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IBI-345 in Solid Tumor Drug Details: IBI-345 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IBI-345 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBI-345 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IBI-345 in Pancreatic Cancer Drug Details: IBI-345 is under development for...
-
Product Insights
Mitochondrial Myopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Mitochondrial Myopathy - Drugs In Development, 2023’, provides an overview of the Mitochondrial Myopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mitochondrial Myopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) – Drugs In Development, 2023
Global Markets Direct’s, ‘MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) - Drugs In Development, 2023’, provides an overview of the MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) pipeline landscape. The report provides comprehensive information on the therapeutics under development for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
NewNet Present Value Model: Takeda Pharmaceutical Co Ltd’s TAK-214
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Q-702 in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Q-702 in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Q-702 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details:Q-702 is under development...